Dr. Satiro De Oliveira, MD
Claim this profileMattel Children's Hospital UCLA
Studies Lymphoma
Studies Tumors
17 reported clinical trials
54 drugs studied
About Satiro De Oliveira, MD
Education:
- Graduated with an MD from Faculdade de Medicina da Universidade de São Paulo, Brazil, in 1995.
Experience:
- Completed an Internal Medicine Internship and Pediatrics Residency at Hospital das Clinicas da FMUSP, Brazil.
- Undertook a Pediatrics Residency at Woodhull Medical & Mental Health Center, New York, in 2007.
- Completed Pediatric Hematology-Oncology Fellowships at Boldrini Children's Center, Brazil, and Children's Hospital of Los Angeles.
Area of expertise
1Lymphoma
Stage IV
Stage I
Stage II
2Tumors
Stage I
Stage II
Stage IV
Affiliated Hospitals
Clinical Trials Satiro De Oliveira, MD is currently running
Selumetinib vs. Chemotherapy
for Brain Cancer
This trial is comparing a new drug, selumetinib, with standard chemotherapy to treat patients with a specific type of brain tumor. The patients do not have a certain genetic mutation and are not affected by a genetic disorder. Selumetinib works by blocking enzymes needed for tumor growth, while the standard drugs kill or stop tumor cells from dividing.
Recruiting2 awards Phase 3
Genetic Testing-Directed Therapy
for Pediatric Cancer
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas.
Recruiting1 award Phase 214 criteria
More about Satiro De Oliveira, MD
Clinical Trial Related4 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Satiro De Oliveira, MD has experience with
- Cyclophosphamide
- Doxorubicin Hydrochloride
- Radiation Therapy
- Tipifarnib
- Selpercatinib
- Cisplatin
Breakdown of trials Satiro De Oliveira, MD has run
Lymphoma
Tumors
Brain Tumor
Germ Cell Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Satiro De Oliveira, MD specialize in?
Satiro De Oliveira, MD focuses on Lymphoma and Tumors. In particular, much of their work with Lymphoma has involved Stage IV patients, or patients who are Stage I.
Is Satiro De Oliveira, MD currently recruiting for clinical trials?
Yes, Satiro De Oliveira, MD is currently recruiting for 7 clinical trials in Los Angeles California. If you're interested in participating, you should apply.
Are there any treatments that Satiro De Oliveira, MD has studied deeply?
Yes, Satiro De Oliveira, MD has studied treatments such as Cyclophosphamide, Doxorubicin Hydrochloride, Radiation Therapy.
What is the best way to schedule an appointment with Satiro De Oliveira, MD?
Apply for one of the trials that Satiro De Oliveira, MD is conducting.
What is the office address of Satiro De Oliveira, MD?
The office of Satiro De Oliveira, MD is located at: Mattel Children's Hospital UCLA, Los Angeles, California 90095 United States. This is the address for their practice at the Mattel Children's Hospital UCLA.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.